AI and Machine Learning Transforming Clinical Trial Efficiency: Insights from SCOPE Europe 2024
核心洞察
Experts at SCOPE Europe 2024 highlighted the increasing role of AI and machine learning in streamlining clinical trial processes, from site selection to patient engagement.
AstraZeneca is scaling up new technologies for use in clinical trials, focusing on patient-facing Digital Health Technologies (DHTs) to improve data collection and patient experience.
Pfizer is leveraging AI and machine learning for predictive analytics, enhancing site intelligence, operational metrics, and quality indicators to ensure timely and precise project delivery.
The integration of artificial intelligence (AI) and machine learning (ML) is rapidly reshaping the landscape of clinical trials, offering unprecedented opportunities to enhance efficiency, reduce costs, and improve patient outcomes. At the recent SCOPE Europe 2024 conference, industry leaders and experts convened to discuss the transformative potential of these technologies in clinical research.
AI-Driven Optimization in Clinical Operations
Nicole Stansbury, Head of Global Clinical Operations at Premier Research (搜索), emphasized the importance of a data-driven approach to streamline clinical trial processes. "We're focused on finding ways to simplify processes and improve technology adoption to decrease the time, cost, complexity, and risk of delivering clinical research," Stansbury noted. Premier Research is leveraging innovative strategies to address the evolving demands of the clinical development industry, with a particular focus on risk-based monitoring and central monitoring.
AstraZeneca's Focus on Digital Health Technologies
Farrell Healion, Head of Emerging Technologies at AstraZeneca, highlighted the company's efforts to scale up new technologies for use in clinical trials. AstraZeneca is particularly focused on patient-facing Digital Health Technologies (DHTs), such as electronic clinical outcome assessments (eCOA), to improve data collection and patient experience. "We are passionate about scaling up the use of patient and site-centric new DHTs in Clinical Trials," Healion stated, emphasizing the importance of engaging with industry work groups to drive innovation in this area.
Predictive Analytics at Pfizer
Jonathan Crowther, Head of Predictive Analytics at Pfizer, discussed the company's use of AI and ML for predictive analytics. Crowther noted that these technologies are instrumental in enhancing site intelligence, operational metrics, and quality indicators. "His prowess in Digital Transformation has been instrumental in the on-time delivery and precision of a diverse suite of predictive models, leveraging ML/AI and Generative AI technologies," Pfizer is committed to data strategies and analytical thinking to ensure timely and precise project delivery, with a focus on process improvement.
The Scope of Things Podcast
The "Scope of Things" podcast, hosted by Clinical Research News, provided a platform for these experts to share their insights and perspectives on the latest trends and challenges in clinical research. The podcast focuses on game-changing trends and out-of-the-box operational approaches in the clinical research field, offering a no-nonsense, insider's look at clinical research today.